Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program.

ABSTRACT:

Objective

Cannabidiol (CBD) treatment was associated with long-term seizure reduction in patients with various treatment-resistant epilepsies who participated in the CBD Expanded Access Program. A phase 3 trial showed CBD effectively treats tuberous sclerosis complex (TSC)-associated seizures, which are primarily of focal origin. However, the effectiveness of CBD in non-TSC focal epilepsies is not well reported. Here, we evaluate CBD treatment outcomes among patients with a variety of focal epilepsies, including TSC.

Methods

Patients received plant-derived highly purified CBD (Epidiolex; 100 mg/mL oral solution) doses starting at 2-10 mg/kg/day and titrated up to each patient's limit or to a maximum of 25-50 mg/kg/day. CBD effectiveness was assessed by the median percentage

SUBMITTER: Patel AD 

PROVIDER: S-EPMC12605695 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature